Program® Plus 2,3 mg/46 mg: Milbemicina oxima (DCI) 2,3 mg, lufenurón (DCI) 46,0 mg
Milbemycin belongs to the group of macrocyclic lactones isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. Selected analogues, the use currently used for therapeutic purposes is milbemycin oxime A3/A4 (ratio ≤ 20 ≥ 80). As one of the active principles Program ® Plus is efficacious against the larval stages (L3, L4, and microfilariae) of Dirofilaria immitis, and possess anthelmintic activity against nematodes following: Toxocara canis, Trichuris vulpis, Ancylostoma caninum. Milbemycin activity correlates with its action on invertebrate neurotransmission: potentiates the effect of GABA (gamma-aminobutyric acid) inhibits neuromuscular transmission, causing paralysis.
The lufenuron belongs to the chemical group benzoylureas and is considered an IGR (Growth Regulator insects) or an IDI (inhibitor of insects). Inhibits flea development by interfering with the normal synthesis, polymerization and deposition of chitin, the main component of the exoskeleton of arthropods. The adult flea lufenuron absorbs your blood collection. At therapeutic levels, lufenuron has no effect on adult fleas but spends transovarially to act on certain insect developmental stages (eggs and larvae), disrupting the insect's life cycle. In addition, the adult flea feces containing lufenuron exert a larvicide when directly ingested by the larvae.
Interactions and incompatibilities
During treatment with Program Plus ® should not be given other antiparasitic macrocyclic lactones.
Indications and species of destination
Dogs: Program ® Plus is used for prevention of flea infestation (C. felis, C. canis, preadult stages), and concurrent prevention of heartworm disease (elimination of L3/L4 larval stages of Dirofilaria immitis) and / or treatment of adult stages of gastrointestinal nematodes such as hookworms (Ancylostoma caninum), roundworms (Toxocara canis) and whip worm (Trichuris vulpis).
Do not use in case of hypersensitivity to the active substances, to any of the excipients or adjuvants.
After treatment has been observed in some dogs pale mucous membranes and increased intestinal peristalsis, lethargy and diarrhea. The treatment of dogs with a high number of circulating microfilariae can sometimes lead to the occurrence of hypersensitivity reactions moderate and transient, such as the presence of paleness of the mucous membranes, vomiting, salivation, labored breathing or excessive. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product.
Route of administration
Oral, once a month.
The Program ® Plus tablets are administered at the rate of a minimum dose of 0.5 mg of milbemycin oxime and 10 mg per kg body weight lufenuron.
If the dog has a high level of infestation by fleas.
|Body weight (kg)||Dosage|
|Hasta 4,5 kg||1 comp./mes||2,3||46|
|De 5 a 11 kg||1 comp./mes||5,75||115|
|De 12 a 22 kg||1 comp./mes||11,5||230|
|De 23 a 45 kg||1 comp./mes||23||460|
If dogs have a high level of flea infestation at the start of treatment, it may be necessary to apply a flea adulticide during the first one to two months. It is important to treat flea all dogs and cats in the house. The cats in the same household should be treated with oral or Program ® injectable suspension.
In heartworm risk regions, or if it is known that a dog has been traveling or risk regions has come from them, before initiating treatment with Program ® Plus, as with any other heartworm preventive, are advised to consult your veterinarian to rule out the presence of concurrent infestation of Dirofilaria immitis. In case of positive diagnosis before administering Program ® Plus adulticide therapy is indicated.
Do not store above 25 ° C.
Keep the blister in the outer carton.
Veterinary medicinal product subject to prescription.
Pack of 6 tablets.
No customer reviews for the moment.